We describe 2 cases of subcutaneous granuloma pyogenicum occurring in patients with antiphospholipid antibodies. The 2 patients had asymptomatic nodules with histopathological findings of a typical subcutaneous granuloma pyogenicum. In addition, case 1 was diagnosed as primary antiphospholipid syndrome with livedo reticularis, superficial thrombophlebitis, thrombocytopenia, cerebral and pulmonary infarcts and renal involvement. Case 2 had no clinical manifestations of vascular occlusive diseases, although anticardiolipin antibody levels were highly positive. To our knowledge, these are the first reported cases of subcutaneous granuloma pyogenicum associated with antiphospholipid antibodies. Antiphospholipid-antibody-mediated thrombosis or immunological mechanisms may be involved in subcutaneous granuloma pyogenicum in our cases.

Keywords:
Subcutaneous granuloma pyogenicum, Antiphospholipid antibody
1.
Cooper PH, Mills SE: Subcutaneous granuloma pyogenicum: Lobular capillary hemangioma. Arch Dermatol 1982;118:30–33.
2.
Wilson WA, Gharavi AE, Koike T, et al: International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an international workshop. Arthritis Rheum 1999;42:1309–1311.
3.
Naldi L, Locati F, Marchesi L, Cortelazzo S, Finazzi G, Galli M, Brevi A, Cainelli T, Barbui T: Cutaneous manifestations associated with antiphospholipid antibodies in patients with suspected primary antiphospholipid syndrome: A case-control study. Ann Rheum Dis 1993;52:219–222.
4.
Mackworth-Young CG, Loizou S, Walport MJ: Primary antiphospholipid syndrome: Features of patients with raised anticardiolipin antibodies and no other disorder. Ann Rheum Dis 1989;48:362–367.
5.
Manganelli P, Lisi R, Saginario A, Benoldi D: Sneddon’s syndrome and primary antiphospholipid syndrome: A case report. J Am Acad Dermatol 1992;26:309–311.
6.
Naldi L, Finazzi G, Brevi A, et al. Antiphospholipid antibodies and melanoma: A link? Dermatology 1992;184:156.
7.
Stephansson EA, Niemi KM: Antiphospholipid antibodies and anetoderma: Are they associated? Dermatology 1995;191:204–209.
8.
Alvarez-Cuesta CC, Raya-Aguado C, Fernandez-Rippe ML, Sanchez TS, Perez-Oliva N: Anetoderma in a systemic lupus erythematosus patient with anti-PCNA and antiphospholipid antibodies. Dermatology 2001;203:348–350.
9.
Carmeliet P: Biomedicine: Clotting factors build blood vessels. Science 2001;293:1602–1604.
10.
Rongioletti F, Rebora A: Cutaneous reactive angiomatoses: Patterns and classification of reactive vascular proliferation. J Am Acad Dermatol 2003;49:887–896.
11.
McMenamin ME, Fletcher CD: Reactive angioendotheliomatosis: A study of 15 cases demonstrating a wide clinicopathologic spectrum. Am J Surg Pathol 2002;26:685–697.
12.
Kim YC, Park HJ, Cinn YW: Microvenular hemangioma. Dermatology 2003;206:161–164.
13.
LeBoit PE, Solomon AR, Santa Cruz DJ, Wick MR: Angiomatosis with luminal cryoprotein deposition. J Am Acad Dermatol 1992;27:969–973.
14.
Creamer D, Black MM, Calonje E: Reactive angioendotheliomatosis in association with the antiphospholipid syndrome. J Am Acad Dermatol 2000;42:903–906.
15.
Thai KE, Barrett W, Kossard S: Reactive angioendotheliomatosis in the setting of antiphospholipid syndrome. Australas J Dermatol 2003;44:151–155.
16.
Reyes E, Alarcon-Segovia D: Leg ulcers in the primary antiphospholipid syndrome: Report of a case with a peculiar proliferative small vessel vasculopathy. Clin Exp Rheumatol 1991;9:63–66.
© 2004 S. Karger AG, Basel
2004
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.